Apogee Therapeutics, Inc.
APGE
$38.69
$2.346.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -100.59% | -98.34% | -116.88% | -109.90% | -72.49% |
| Total Depreciation and Amortization | 1,023.08% | 1,165.52% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 421.32% | 475.61% | 309.91% | -9.69% | -65.02% |
| Change in Net Operating Assets | -592.90% | -188.78% | -132.79% | -1.70% | -76.03% |
| Cash from Operations | -99.64% | -96.18% | -128.96% | -139.21% | -156.86% |
| Capital Expenditure | -925.48% | -888.03% | -589.82% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.35% | 29.07% | -9.34% | -64.46% | -- |
| Cash from Investing | 98.12% | 27.61% | -9.69% | -65.03% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.98% | -94.13% | 56.80% | 42.75% | -- |
| Repurchase of Common Stock | -8,897.80% | -15,304.69% | -15,304.69% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1,850.71% | -- | -- | 4,534.98% | 169.45% |
| Cash from Financing | -93.94% | -94.10% | 56.98% | -7.94% | 333.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -200.32% | -209.91% | 170.53% | -134.69% | 36.31% |